Pfizer Inc. stock slips as BMO Capital keeps positive stance and options activity spikes
Published on 09/09/2026 at 18:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pfizer Inc. stock (ISIN US7170811035) closed at USD 27.79 on the New York Stock Exchange on September 8, 2026, down 2.32% from the prior session but still roughly 11.6% above recent lows, as the pharmaceutical group digests a mixed post-pandemic outlook and heightened options activity around the shares.
Recent earnings and guidance support the stock
According to The Globe and Mail, Pfizer reported its second-quarter 2026 results on August 4, 2026, with revenue rising 3% year over year to USD 15.0 billion, while adjusted net income increased marginally to USD 4.4 billion or USD 0.77 per share, slightly above analyst expectations.
In the same report, the company raised the low end of its full-year 2026 revenue guidance, now expecting between USD 60.5 billion and USD 62.5 billion compared with a previous range of USD 59.5 billion to USD 62.5 billion, which implies that non-COVID products are offsetting weaker volumes in COVID-19 treatments and vaccines.The Globe and Mail
Analyst views and valuation context
As Zacks reported on September 9, 2026, Pfizer stock has gained 8.6% over the past three months, supported by improving sentiment as higher revenue from non-COVID products more than offsets declines in COVID-19 vaccine Comirnaty and antiviral Paxlovid, and the shares recently touched a fresh 52-week high on September 3, 2026.
Zacks also highlighted that Pfizer expects total revenues for 2026 in a range of USD 60.5 billion to USD 62.5 billion, compared with 2025 revenues of USD 62.6 billion, while adjusted earnings per share are guided to USD 2.80 to USD 3.00 versus USD 3.22 in 2025, implying a modest revenue decline but a more pronounced EPS impact from deal-related dilution, lower COVID revenues and higher taxes.Zacks
Based on data compiled by MarketBeat on September 8, 2026, Pfizer currently carries a consensus Hold rating with a consensus target price of USD 28.28, only slightly above the latest closing price, suggesting that analysts see limited near-term upside while they wait for clearer evidence that the non-COVID portfolio can drive top-line growth.
Options activity and recent deals shape risk perception
According to Moomoo data summarized on September 8, 2026, options trading in Pfizer surged with about 150,200 contracts changing hands, of which 57.52% were put options and 42.48% call options, and the most notable single trade was a put option with a strike price of USD 28.00 and a notional value of roughly USD 1.93 million when the underlying stock traded at USD 27.89, pointing to active hedging or speculative positioning around the current price level.
Meanwhile, MarketScreener noted that BMO Capital remains positive on Pfizer as of September 8, 2026, even as the stock closed at USD 27.79 on the NYSE, down 2.32% on the day, indicating that at least some institutional research houses still see value in the shares despite near-term volatility and the looming loss of exclusivity on several key products.
Stock level, 52-week range and investor takeaway
Pfizer stock’s closing price of USD 27.79 on September 8, 2026 on the NYSE sits modestly below the consensus target of USD 28.28 and around 11.6% above lows referenced in recent coverage, leaving the shares trading in the lower part of their 12-month range but clearly above the worst levels seen earlier in the year.
Pfizer Inc. stock profile
- Company: Pfizer Inc.
- ISIN: US7170811035
- Ticker: PFE
- Trading venue: NYSE
- Price (as of September 8, 2026, 22:01): 27.79 USD
- Market capitalization: 157,000,000,000 USD (as of September 8, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500
